346 related articles for article (PubMed ID: 15588721)
21. Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7).
Allegra CJ; Boarman D
Cancer Res; 1990 Jun; 50(12):3574-8. PubMed ID: 1692762
[TBL] [Abstract][Full Text] [Related]
22. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
23. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
24. Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP).
Markowicz-Piasecka M; Huttunen J; Montaser A; Adla SK; Auriola S; Lehtonen M; Huttunen KM
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299347
[TBL] [Abstract][Full Text] [Related]
25. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
26. Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport.
Ji Y; Morris ME
Pharm Res; 2004 Dec; 21(12):2261-9. PubMed ID: 15648258
[TBL] [Abstract][Full Text] [Related]
27. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of the human folate receptor mediates transport-defective methotrexate resistance in KB cells.
Saikawa Y; Knight CB; Saikawa T; Page ST; Chabner BA; Elwood PC
J Biol Chem; 1993 Mar; 268(7):5293-301. PubMed ID: 7680349
[TBL] [Abstract][Full Text] [Related]
29. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.
Wielinga P; Hooijberg JH; Gunnarsdottir S; Kathmann I; Reid G; Zelcer N; van der Born K; de Haas M; van der Heijden I; Kaspers G; Wijnholds J; Jansen G; Peters G; Borst P
Cancer Res; 2005 May; 65(10):4425-30. PubMed ID: 15899835
[TBL] [Abstract][Full Text] [Related]
30. Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
[TBL] [Abstract][Full Text] [Related]
31. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
Nakanishi T; Doyle LA; Hassel B; Wei Y; Bauer KS; Wu S; Pumplin DW; Fang HB; Ross DD
Mol Pharmacol; 2003 Dec; 64(6):1452-62. PubMed ID: 14645676
[TBL] [Abstract][Full Text] [Related]
32. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
33. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.
Jolivet J; Schilsky RL; Bailey BD; Drake JC; Chabner BA
J Clin Invest; 1982 Aug; 70(2):351-60. PubMed ID: 6178756
[TBL] [Abstract][Full Text] [Related]
35. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
36. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
Dixon KH; Trepel JB; Eng SC; Cowan KH
Cancer Commun; 1991; 3(12):357-65. PubMed ID: 16296001
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
38. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
Kager L; Cheok M; Yang W; Zaza G; Cheng Q; Panetta JC; Pui CH; Downing JR; Relling MV; Evans WE
J Clin Invest; 2005 Jan; 115(1):110-7. PubMed ID: 15630450
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
[TBL] [Abstract][Full Text] [Related]
40. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
